| abstract |
The present invention provides a safe, stable, effective and cost-effective vaccine based on a viral expression vector comprising a parainfluenza virus type 5 (PIV5) genome comprising a heterologous nucleotide sequence expressing a heterologous polypeptide. . In some embodiments, the heterologous nucleotide sequence is inserted closer to the leader than between the hemagglutinin-neuraminidase (HN) gene and the large RNA polymerase protein (L) gene of the PIV5 genome. In some embodiments, the heterologous nucleotide sequence is inserted between the small hydrophobic protein (SH) gene and the hemagglutinin-neuraminidase (HN) gene of the PIV5 genome. [Selection] Figure 3A |